Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1977 Mar;297(1):23-9.
doi: 10.1007/BF00508806.

Effects of neuroleptics on release of 3H-dopamine from slices of rat corpus striatum

Effects of neuroleptics on release of 3H-dopamine from slices of rat corpus striatum

K Dismukes et al. Naunyn Schmiedebergs Arch Pharmacol. 1977 Mar.

Abstract

The characteristics of 3H-DA release from striatal slices by electrical stimulation were analyzed and the effects of a number of neuroleptics thereon were examined under different experimental conditions. The butyrophenones, haloperidol and spiroperidol, already at low concentrations (0.1 - 1 micronM) increased basal tritium efflux in a dose-dependent manner. The phenothiazines, chlorpromazine and fluphenazine, were much less effective in this respect. The butyrophenones strongly inhibited the electrically stimulated overflow of both 3H-DA and 14C-GABA, while the phenothiazines again had little effect. The action of 1 micronM haloperidol on 3H-DA release could be blocked by 10 micronM cocaine, but not with 1 micronM apomorphine. Apomorphine itself had no significant effect on 3H-DA release. Our data do not support the suggestion that presynaptic DA receptors on dopaminergic nerve terminals may modulate the release of newly taken-up 3H-DA. Some neuroleptics, particularly the butyrophenones may have presynaptic effects not related to interaction with DA receptors. It is suggested that different mechanisms may be involved in the local presynaptic receptor-mediated feedback regulation of transmitter release in noradrenergic and dopaminergic systems in the CNS.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Mol Pharmacol. 1976 Mar;12(2):251-62 - PubMed
    1. Eur J Pharmacol. 1974 Aug;27(3):273-80 - PubMed
    1. Brain Res. 1975 Dec 5;99(2):419-24 - PubMed
    1. J Pharmacol Exp Ther. 1974 Sep;190(3):431-50 - PubMed
    1. Acta Physiol Scand. 1974 Jan;90(1):158-65 - PubMed

LinkOut - more resources